CLOVER BIO-B

2197
1.6550.60% ( -0.010 )
Delay Closed: Nov 16, 16:08:11

Overview

CLOVER BIO-B (2197)

Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland Ch...

Open
1.660
High
1.675
Low
1.590
Prev. Close
1.665
Volume
2.15M
Turnover
3.52M
Avg Price
1.633
Bid/Ask Ratio
37.84%
Amplitude
5.11%
52wk High
3.200
Volume Ratio
0.32
Turnover Ratio
0.17%
52wk Low
1.110
HK Mkt Cap
2.15B
Market CapHKD
2.15B
P/ETTM
2.19
P/EDynamic
0.98
P/EStatic
--
EPSTTM
0.755
EPSDynamic
1.69
EPSStatic
--
BVPS
-0.71
P/B
--
HK Shares
1.30B
Dividend YieldTTM
--
DividendTTM
--
Shares
1.30B
Min lot size
500
Currency
HKD

CLOVER BIO-B Analyst Rating

View more

Forecast & Rating

Jan 9, 2024
Price forecast
HK$2.8873.93%
Forecast & RatingHold
1analysts
  • Strong buy0.00%
  • Buy0.00%
  • Hold100.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Jul, 3

    Clover Biopharmaceuticals rallied in the afternoon session, climbing from a session low of 1.66 HKD to an intraday high of 1.79 HKD, before closing at 1.77 HKD, up 4.1% from the previous close of 1.70 HKD, with an intraday range of 8.2%. The move was catalyzed by news of a cap-limited settlement with Gavi to terminate arbitration, alleviating a US$224 million exposure. Year-to-date, the stock is down 25.3%, trading 44.7% below its 52-week high of 3.2 HKD. While the current price sits above the 20-day moving average (1.66 HKD), it remains below the 60-day moving average (2.37 HKD). Q4 revenue plunged 99.5% YoY to HK$140 thousand, though net loss narrowed 86.6%, with EPS improving to -0.046 HKD. Net profit margin, however, remains deeply negative, underscoring the distance to a sustainable recovery.

News